

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/697,545	10/25/2000	Guangyi Wang	213/001-US4	7524
7	590 01/23/2003			
Robert D. Fish Rutan & Tucker, LLP			EXAMINER	
P.O. Box 1950 Suite 706			RILEY, JEZIA	
Costa Mesa, CA 92628-1950			ART UNIT	PAPER NUMBER
			1637 DATE MAILED: 01/23/2003	10

Please find below and/or attached an Office communication concerning this application or proceeding.

•						
	Application No.	Applicant(s)				
Office Action Summany	09/697,545	WANG, GUANGYI				
Office Action Summary	Examiner	Art Unit				
The MAN INC DATE of this case of the	Jezia Riley	1637				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period with a Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	6(a). In no event, however, may a new within the statutory minimum of thin ill apply and will expire SIX (6) MON cause the application to become AB	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. 3ANDONED (35 U.S.C. § 133)				
1) Responsive to communication(s) filed on						
2a) ☐ This action is FINAL . 2b) ☐ This	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>1-74</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-74 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)	. •	- ··				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of I	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152) .				

Application/Control Number: 09/697,545

Art Unit: 1637

DETAILED ACTION

The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claims 1-20 have been renumbered 55-74.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Group I. Claims 1-12, drawn to a 1st compound; classified in Class 536, subclass 22.1.
- Group II. Claims 13-24, drawn to a 2nd compound; classified in Class 536, subclass 22.1.
- Group III. Claims 25-36, drawn to a 3rd compound; classified in Class 536, subclass 22.1.
- Group IV. Claims 37-48, drawn to a 4th compound; classified in Class 536, subclass 22.1.
- Group V. Claims 49, drawn to a 5th compound; classified in Class 536, subclass 22.1.
- Group VI. Claim 50, drawn to a 6th compound; classified in Class 536, subclass 22.1.
- Group VII. Claim 51, drawn to a 1st polynucleotide comprising 1st compound; classified in Class 536, subclass 22.1.
- Group VIII. Claim 52, drawn to a 2nd polynucleotide comprising 2nd compound; classified in Class 536, subclass 22.1.
- Group IX. Claim 53, drawn to a 3rd polynucleotide comprising 3rd compound; classified in Class 536, subclass 22.1.

Application/Control Number: 09/697,545

Art Unit: 1637

Group X. Claim 54, drawn to a 4th polynucleotide comprising 4th compound; classified in Class 536, subclass 22.1.

Group XI. Claim 55-74, drawn to a 7th compound; classified in Class 536, subclass 22.1.

2. The inventions are distinct, each from the other because of the following reasons:

Inventions I-XI are different inventions because they are directed to different species.

Inventions I-VI and VII-XI are distinct because the instant monomeric nucleotides of Group I-VI can be used in a materially different process of using that product as contrasted with the use of these monomers into oligomer. The materially different process of use is in methods of inhibition as substrate analogs or alternatively as in-vivo enzymatic inhibitors of which many mononucleotides are well known.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 703-305-6855. The examiner can normally be reached on 9:30AM - 5:00PM.

Application/Control Number: 09/697,545

Art Unit: 1637

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

JEZIA RILEY PRIMARY FYAMINER

January 22, 2003